GlassScriptPhysician profile
Paul G Rutledge
NPI 1497763783
$15,642.88
in general payments reported to CMS, 2019-2025
67 companies · $2,064 in 2025
The $2,064 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,998 · 2020: $1,540 · 2021: $2,353 · 2022: $2,511 · 2023: $2,506 · 2024: $2,671 · 2025: $2,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,219 · Education: $21.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,218.95 |
| Education | $21.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,759.69 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,378.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,017.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $933.14 | 2019-2025 | |
| Novo Nordisk INC | $902.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $667.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $625.92 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.68 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $437.43 | 2019-2024 | Xarelto, Spravato |
| Otsuka America Pharmaceutical, INC. | $430.86 | 2019-2025 | Rexulti, Jynarque |
| Allergan, INC. | $426.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $380.09 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.47 | 2019-2025 | Jardiance |
| Abbott Laboratories | $253.13 | 2021-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.24 | 2022-2025 | Caplyta |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rutledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.